These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32103184)

  • 21. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation.
    Ng BG; Buckingham KJ; Raymond K; Kircher M; Turner EH; He M; Smith JD; Eroshkin A; Szybowska M; Losfeld ME; Chong JX; Kozenko M; Li C; Patterson MC; Gilbert RD; Nickerson DA; Shendure J; Bamshad MJ; ; Freeze HH
    Am J Hum Genet; 2013 Apr; 92(4):632-6. PubMed ID: 23561849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort.
    Lam C; Scaglia F; Berry GT; Larson A; Sarafoglou K; Andersson HC; Sklirou E; Tan QKG; Starosta RT; Sadek M; Wolfe L; Horikoshi S; Ali M; Barone R; Campbell T; Chang IJ; Coles K; Cook E; Eklund EA; Engelhardt NM; Freeman M; Friedman J; Fu DYT; Botzo G; Rawls B; Hernandez C; Johnsen C; Keller K; Kramer S; Kuschel B; Leshinski A; Martinez-Duncker I; Mazza GL; Mercimek-Andrews S; Miller BS; Muthusamy K; Neira J; Patterson MC; Pogorelc N; Powers LN; Ramey E; Reinhart M; Squire A; Thies J; Vockley J; Vreugdenhil H; Witters P; Youbi M; Zeighami A; Zemet R; Edmondson AC; Morava E
    Mol Genet Metab; 2024 Aug; 142(4):108509. PubMed ID: 38959600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up.
    Bogdańska A; Lipiński P; Szymańska-Rożek P; Jezela-Stanek A; Rokicki D; Socha P; Tylki-Szymańska A
    Orphanet J Rare Dis; 2021 Jan; 16(1):17. PubMed ID: 33407696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.
    Radenkovic S; Johnsen C; Schulze A; Lail G; Guilder L; Schwartz K; Schultz M; Mercimek-Andrews S; Boyer S; Morava E
    Ther Adv Rare Dis; 2023; 4():26330040221150269. PubMed ID: 37181075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG.
    Morava E
    Mol Genet Metab; 2014 Aug; 112(4):275-9. PubMed ID: 24997537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four New Cases of SLC35A2-CDG With Novel Mutations and Clinical Features.
    Abuduxikuer K; Wang JS
    Front Genet; 2021; 12():658786. PubMed ID: 34122512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
    Durin Z; Houdou M; Morelle W; Barré L; Layotte A; Legrand D; Ouzzine M; Foulquier F
    Front Cell Dev Biol; 2022; 10():903953. PubMed ID: 35693943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLC35A2 Deficiency Promotes an Epithelial-to-Mesenchymal Transition-like Phenotype in Madin-Darby Canine Kidney Cells.
    Kot M; Mazurkiewicz E; Wiktor M; Wiertelak W; Mazur AJ; Rahalevich A; Olczak M; Maszczak-Seneczko D
    Cells; 2022 Jul; 11(15):. PubMed ID: 35892570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
    Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
    Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy.
    Kodera H; Nakamura K; Osaka H; Maegaki Y; Haginoya K; Mizumoto S; Kato M; Okamoto N; Iai M; Kondo Y; Nishiyama K; Tsurusaki Y; Nakashima M; Miyake N; Hayasaka K; Sugahara K; Yuasa I; Wada Y; Matsumoto N; Saitsu H
    Hum Mutat; 2013 Dec; 34(12):1708-14. PubMed ID: 24115232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDG Therapies: From Bench to Bedside.
    Brasil S; Pascoal C; Francisco R; Marques-da-Silva D; Andreotti G; Videira PA; Morava E; Jaeken J; Dos Reis Ferreira V
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29702557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new D-galactose treatment monitoring index for PGM1-CDG.
    Perales-Clemente E; Liedtke K; Studinski A; Radenkovic S; Gavrilov D; Oglesbee D; Matern D; Rinaldo P; Tortorelli S; Morava E; Raymond K
    J Inherit Metab Dis; 2021 Sep; 44(5):1263-1271. PubMed ID: 34043239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.
    Medrano C; Vega A; Navarrete R; Ecay MJ; Calvo R; Pascual SI; Ruiz-Pons M; Toledo L; García-Jiménez I; Arroyo I; Campo A; Couce ML; Domingo-Jiménez MR; García-Silva MT; González-Gutiérrez-Solana L; Hierro L; Martín-Hernández E; Martínez-Pardo M; Roldán S; Tomás M; Cabrera JC; Mártinez-Bugallo F; Martín-Viota L; Vitoria-Miñana I; Lefeber DJ; Girós ML; Serrano Gimare M; Ugarte M; Pérez B; Pérez-Cerdá C
    Clin Genet; 2019 May; 95(5):615-626. PubMed ID: 30653653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation.
    van Scherpenzeel M; Steenbergen G; Morava E; Wevers RA; Lefeber DJ
    Transl Res; 2015 Dec; 166(6):639-649.e1. PubMed ID: 26307094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congenital disorders of glycosylation with emphasis on cerebellar involvement.
    Barone R; Fiumara A; Jaeken J
    Semin Neurol; 2014 Jul; 34(3):357-66. PubMed ID: 25192513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-mannose as a new therapy for fucokinase deficiency-related congenital disorder of glycosylation (FCSK-CDG).
    Starosta RT; Lee AJ; Toolan ER; He M; Wongkittichote P; Daniel EJP; Radenkovic S; Budhraja R; Pandey A; Sharma J; Morava E; Nguyen H; Dickson PI
    Mol Genet Metab; 2024 Jun; 142(2):108488. PubMed ID: 38735264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-Phenotype Correlations in PMM2-CDG.
    Vaes L; Rymen D; Cassiman D; Ligezka A; Vanhoutvin N; Quelhas D; Morava E; Witters P
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Congenital Disorders of Glycosylation in Childhood Epilepsy and Effects of Anti-Epileptic Drugs on the Transferrin Isoelectric Focusing Test.
    Silver G; Bahl S; Cordeiro D; Thakral A; Athey T; Mercimek-Andrews S
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination.
    Miyamoto S; Nakashima M; Ohashi T; Hiraide T; Kurosawa K; Yamamoto T; Takanashi J; Osaka H; Inoue K; Miyazaki T; Wada Y; Okamoto N; Saitsu H
    Mol Genet Genomic Med; 2019 Aug; 7(8):e814. PubMed ID: 31231989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal expression of lysosomal glycoproteins in patients with congenital disorders of glycosylation.
    Sabry S; Eissa NR; Zaki MS
    BMC Res Notes; 2023 Apr; 16(1):53. PubMed ID: 37069668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.